I very much agree with that sentiment. This company has internal connections with Pfizer and a product-in-development that has shown great potential. I'm uncertain as to the calculus of larger pharmaceuticals, but we know some are "ballsier" than others, ala Gilead. A partnership would be a boon for the little guy long investors and a major stabilizing factor for the security as a whole.
I'm wondering how much more positive data will be required for a larger pharmaceutical to jump in. Then again, a deal could be in the works right now, and we'd never know. Every morning at 7:00 AM is a potential Christmas!